
|Videos|March 17, 2022
Dr. Petrylak on important updates in bladder cancer from NY GU 2022
Author(s)Urology Times staff
“There are many trials that clinicians should be aware of,” says Daniel P. Petrylak, MD.
Advertisement
In this video, Daniel P. Petrylak, MD, PhD, discusses major takeaways and ongoing research in urothelial cancer, which was presented on at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies. Petrylak is the director of genitourinary oncology, a professor of medicine and urology, co-leader of Cancer Signaling Networks, and co-director of the Signal Transduction Program at the Yale University Cancer Center in New Haven, Connecticut.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves sildenafil oral film for men with erectile dysfunction
2
The UroOnc Minute: Adjuvant Therapy in Renal Cell Carcinoma, with Brian Shuch, MD
3
URO-1 prostate biopsy devices adopted across Novant Health System as clinical study continues
4
Sarah Azari, MD, on early sexual health education for women with bladder cancer
5






